Farmaceutici S.P.A. Fidia Net Worth

The estimated Net Worth of Farmaceutici S.P.A. Fidia is at least $48.4 Million dollars as of 6 August 2013. Farmaceutici Fidia owns over 1,270,000 units of Anika Therapeutics stock worth over $17,246,406 and over the last 11 years Farmaceutici sold ANIK stock worth over $31,140,400.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Farmaceutici Fidia ANIK stock SEC Form 4 insiders trading

Farmaceutici has made over 1 trades of the Anika Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently Farmaceutici sold 1,270,000 units of ANIK stock worth $31,140,400 on 6 August 2013.

The largest trade Farmaceutici's ever made was selling 1,270,000 units of Anika Therapeutics stock on 6 August 2013 worth over $31,140,400. On average, Farmaceutici trades about 1,270,000 units every 0 days since 2013. As of 6 August 2013 Farmaceutici still owns at least 711,192 units of Anika Therapeutics stock.

You can see the complete history of Farmaceutici Fidia stock trades at the bottom of the page.

What's Farmaceutici Fidia's mailing address?

Farmaceutici's mailing address filed with the SEC is VIA PONTE DELLA FABBRICA 3/A, , ABANO TERME (PD), L6, CAP 35031.

Insiders trading at Anika Therapeutics

Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia, and Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.

What does Anika Therapeutics do?

who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an

Complete history of Farmaceutici Fidia stock trades at Anika Therapeutics

Anika Therapeutics executives and stock owners

Anika Therapeutics executives and other stock owners filed with the SEC include:

• James Loerop,
  Executive Vice President - Business Development and Strategic Planning
• Thomas Finnerty,
  Executive Vice President of Human Resources
• Dr. Cheryl Renee Blanchard Ph.D.,
  Pres, CEO & Director
• David Colleran,
  Exec. VP, Gen. Counsel & Corp. Sec.
• James Loerop,
  Exec. VP of Bus. Devel. & Strategic Planning
• Michael L. Levitz,
  Exec. VP, CFO & Treasurer
• Thomas M. Finnerty,
  Exec. VP of HR
• Joseph Bower,
  Independent Chairman of the Board
• Jeffery Thompson,
  Independent Director
• Raymond Land,
  Independent Director
• Glenn Larsen,
  Independent Director
• Cheryl Blanchard,
  President, Chief Executive Officer, Director
• Susan Vogt,
  Independent Director
• Dr. Cheryl R. Blanchard,
  Pres, CEO & Director
• Stephen Richard,
  Independent Director
• John Henneman,
  Independent Director
• David Colleran,
  Executive Vice President, General Counsel, Secretary
• Michael Levitz,
  Chief Financial Officer, Executive Vice President, Treasurer
• Anne Nunes,
  VP of Operations
• Bart Bracy,
  VP of Sales & Marketing of Americas
• James Chase,
  Sr. VP of International Sales & Marketing
• Charles Sherwood III,
  VP & Corp. Legal Counsel
• Mark Namaroff,
  Exec. Director of Investor Relations & Corp. Communications
• Alexei Goraltchouk,
  Sr. VP of Operations & Project Management
• Richard Hague,
  Chief Commercial Officer
• Edward S. Ahn,
  Chief Tech. & Strategy Officer
• Charles H Sherwood,
  President and CEO
• Sylvia Cheung,
  Chief Financial Officer
• Steve E Wheeler,
  Director
• Dana M. Alexander,
  Chief Operations Officer
• Stephen R. Mascioli,
  Chief Medical Officer
• John C Moran,
  Director
• Joseph G Darling,
  President and CEO; Director
• Gary P Fischetti,
  Director
• Sheryl L Conley,
  Director
• John W Jr Sheets,
  Chief Scientific Officer
• Farmaceutici S.P.A. Fidia,
  10% owner
• Peter Litman,
  VP, Business Development
• William J Knight,
  Chief Financial Officer
• Harvey S Sadow,
  Director
• William Mrachek,
  V.P., Human Resources
• Samuel F Mckay,
  Director
• Eugene A Davidson,
  Director
• Francesco J Luppino,
  Chief Operating Officer
• Carol A Barnett,
  Chief Commercial Officer
• Kevin W Quinlan,
  Chief Financial Officer
• Constance H Garrison,
  VP Reg.,Clinical & Qlty. Sys.
• James E O Neill,
  Chief Accounting Officer
• Carol A Toth,
  Vice President, R & D
• Elizabeth Chen,
  Sr. VP Mktg. & Bus. Dev.
• Anne Nunes,
  SVP, Chief Operations Officer
• Stephen D. Griffin,
  EVP, CFO and Treasurer
• Joseph H Capper,
  Director
• William R Jellison,
  Director